Strata Critical Co-CEO shares withheld for taxes

Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn reported a tax-related share disposition.

Accepted by SEC EDGAR 03/10/2026 - 05:28 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Strata Critical Medical, Inc. director and Co-CEO/CFO William A. Heyburn reported a tax-related share disposition. On March 8, 2026, 31,314 shares of Class A common stock were withheld by the company to satisfy tax obligations tied to vesting restricted stock units, rather than sold on the open market. After this withholding, Heyburn directly holds 1,336,774 shares of Class A common stock.

Insider Trade Summary

Exercise Price or Tax Liability: 31,314 shares

Exercise Price or Tax Liability 1 txn

Insider Heyburn William A.

Role Co-CEO and CFO

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Class A common stock, $0.0001 par value per share	31,314	$4.54	$142K

Holdings After Transaction: Class A common stock, $0.0001 par value per share — 1,336,774 shares (Direct)

Holdings Before and After: Class A common stock, $0.0001 par value per share, 1,368,088 to 1,336,774 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Strata Critical Medical (SRTA) report for William A. Heyburn?

Strata Critical Medical reported that Co-CEO and CFO William A. Heyburn had 31,314 shares withheld to cover tax obligations from vesting restricted stock units. This was a tax-withholding disposition, not an open-market sale or purchase of shares.

How many Strata Critical Medical shares were withheld for taxes in this Form 4?

The Form 4 shows that 31,314 shares of Strata Critical Medical Class A common stock were withheld. These shares satisfied tax withholding obligations arising from the vesting of restricted stock units granted to William A. Heyburn as part of his equity compensation.

Does the Strata Critical Medical Form 4 indicate an open-market sale of SRTA shares?

No, the Form 4 does not indicate an open-market sale. It reports a code F transaction, meaning 31,314 shares were withheld by the issuer solely to cover tax liabilities from vesting restricted stock units, rather than being sold to third-party buyers in the market.

How many Strata Critical Medical shares does William A. Heyburn hold after this tax withholding?

After the tax-withholding transaction, William A. Heyburn directly holds 1,336,774 shares of Strata Critical Medical Class A common stock. This figure reflects his remaining direct ownership following the 31,314 shares withheld to satisfy his equity-related tax obligations.

What does transaction code F mean in this Strata Critical Medical Form 4?

Transaction code F indicates payment of an exercise price or tax liability by delivering or withholding securities. In this case, 31,314 SRTA shares were withheld by Strata Critical Medical to satisfy William A. Heyburn’s tax obligations from vesting restricted stock units.

Who is the insider involved in the latest Strata Critical Medical Form 4 filing?

The insider is William A. Heyburn, who serves as both Co-CEO and Chief Financial Officer of Strata Critical Medical. He is also a director of the company, and the reported Form 4 transaction relates to his equity compensation tax withholding.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heyburn William A.

(Last) (First) (Middle)

C/O STRATA CRITICAL MEDICAL, INC.

31 HUDSON YARDS, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Strata Critical Medical, Inc. [ SRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Co-CEO and CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A common stock, $0.0001 par value per share	03/08/2026		F		31,314(1)	D	$4.54	1,336,774	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

Remarks:

	/s/ Melissa M. Tomkiel, as attorney-in-fact for William A. Heyburn	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.